Analysis of single-agent, combination, and novel bispecific antibodies revealed a positive landscape of treatment for patients with diffuse large B-cell lymphoma (DLBCL). R/R DLBCL represents a major ...

—In a Danish registry study, patients with DLBCL who received R-CHOP-like therapies had an increased risk of infections, autoimmune conditions, and immune deficiencies compared with a matched ...

Researchers identified nearly 50,000 patients diagnosed with DLBCL over a 15-year period to measure the impact of SES on 5-year overall survival (OS). Patients living in low SES regions had ...

Capivasertib and venetoclax combination shows efficacy in PTEN-wildtype and PTEN-deficient diffuse large B-cell lymphoma (DLBCL) models, inducing caspase and PARP cleavage and inhibiting tumor growth.

About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...